<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37285617</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Cutaneous lupus erythematosus is associated with an increased risk of cardiac and vascular diseases: a large-scale, propensity-matched global retrospective cohort study.</ArticleTitle><Pagination><StartPage>104639</StartPage><MedlinePgn>104639</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">104639</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2023.104639</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(23)00204-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Autoimmune skin diseases can expedite various systemic sequelae involving other organs. Although limited to the skin, cutaneous lupus erythematosus (CLE) was noted to be associated with thromboembolic diseases. However, small cohort sizes, partially discrepant outcomes, missing data on CLE subtypes, and incomplete risk assessment limits these findings.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Global Collaborative Network of TriNetX provides access to medical records of more than 120 million patients worldwide. We used TriNetX to elucidate the risk for cardiac and vascular diseases after diagnosis of CLE, and its subtypes chronic discoid (DLE) and subacute cutaneous lupus erythematosus (SCLE). We included 30,315 CLE, 27,427 DLE, and 1613 SCLE patients. We performed propensity-matched cohort studies determining the risk to develop cardiac and vascular diseases (ICD10CM:I00-99) following diagnosis of CLE, DLE, or SCLE. Patients with systemic lupus erythematosus were excluded.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">We document that CLE and its subtype DLE but less so SCLE are associated with a higher risk for various cardiac and vascular diseases. This included predominantly thromboembolic events such as pulmonary embolism, cerebral infarction, and acute myocardial infarction, but also peripheral vascular disease and pericarditis. For example, the hazard ratio of arterial embolism and thrombosis was 1.399 (confidence interval: 1.230-1.591, p&#xa0;&lt;&#xa0;0.0001) following CLE diagnosis. The study is limited by retrospective data collection and reliance on ICD10-disease classification.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">CLE and its major subtype DLE are associated with an increased risk for the development of a wide range of cardiac and vascular diseases.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">This research was funded by Deutsche Forschungsgemeinschaft (EXC 2167, CSSL/CS01-2022) and the Excellence-Chair Program of the State of Schleswig-Holstein.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olbrich</LastName><ForeName>Henning</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of L&#xfc;beck, L&#xfc;beck, Germany. Electronic address: henning.olbrich@uksh.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kridin</LastName><ForeName>Khalaf</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>L&#xfc;beck Institute of Experimental Dermatology, University of L&#xfc;beck, L&#xfc;beck, Germany; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel; Unit of Dermatology and Skin Research Laboratory, Barch Padeh Medical Center, Poriya, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zirpel</LastName><ForeName>Henner</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Comprehensive Center for Inflammation Medicine, University-Hospital Schleswig-Holstein, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadik</LastName><ForeName>Christian D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terheyden</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tha&#xe7;i</LastName><ForeName>Diamant</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Comprehensive Center for Inflammation Medicine, University-Hospital Schleswig-Holstein, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludwig</LastName><ForeName>Ralf J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of L&#xfc;beck, L&#xfc;beck, Germany; L&#xfc;beck Institute of Experimental Dermatology, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boch</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008179" MajorTopicYN="Y">Lupus Erythematosus, Discoid</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008178" MajorTopicYN="Y">Lupus Erythematosus, Cutaneous</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014652" MajorTopicYN="Y">Vascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular disease</Keyword><Keyword MajorTopicYN="N">Cutaneous lupus</Keyword><Keyword MajorTopicYN="N">Lupus</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Stroke</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare that this study was designed and conducted in the absence of any financial or commercial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>7</Day><Hour>19</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>7</Day><Hour>18</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37285617</ArticleId><ArticleId IdType="pmc">PMC10279782</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2023.104639</ArticleId><ArticleId IdType="pii">S2352-3964(23)00204-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Durosaro O., Davis M.D.P., Reed K.B., Rohlinger A.L. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol. 2009;145(3):249&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3953616</ArticleId><ArticleId IdType="pubmed">19289752</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen M.P., M&#xf6;ller S., Bygum A., Voss A., Bliddal M. Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark. Lupus. 2018;27(9):1424&#x2013;1430.</Citation><ArticleIdList><ArticleId IdType="pubmed">29788808</ArticleId></ArticleIdList></Reference><Reference><Citation>Werth V.P. Clinical manifestations of cutaneous lupus erythematosus. Autoimmun Rev. 2005;4(5):296&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">15990077</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R.S., Morganroth P.A., Werth V.P. Cutaneous lupus and the cutaneous lupus erythematosus disease area and severity index instrument. Rheum Dis Clin North Am. 2010;36(1):33&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3035848</ArticleId><ArticleId IdType="pubmed">20202590</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R., Moghadam-Kia S., Taylor L., et al. Quality of life in cutaneous lupus erythematosus. J&#xa0;Am Acad Dermatol. 2011;64(5):849&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3079065</ArticleId><ArticleId IdType="pubmed">21397983</ArticleId></ArticleIdList></Reference><Reference><Citation>Drenkard C., Barbour K.E., Greenlund K.J., Lim S.S. The burden of living with cutaneous lupus erythematosus. Front Med. 2022;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9395260</ArticleId><ArticleId IdType="pubmed">36017007</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesselvig J.H., Egeberg A., Kofoed K., Gislason G., Dreyer L. Increased risk of depression in patients with cutaneous lupus erythematosus and systemic lupus erythematosus: a Danish nationwide cohort study. Br J Dermatol. 2018;179(5):1095&#x2013;1101.</Citation><ArticleIdList><ArticleId IdType="pubmed">29885269</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xf6;nhagen C.M., Fored C.M., Granath F., Nyberg F. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden: incidence of cutaneous lupus erythematosus in Sweden. Br J Dermatol. 2011;164(6):1335&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pubmed">21574972</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieczorek I.T., Propert K.J., Okawa J., Werth V.P. Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus. JAMA Dermatol. 2014;150(3):291.</Citation><ArticleIdList><ArticleId IdType="pubmed">24477339</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtiss P., Walker A.M., Chong B.F. A&#xa0;systematic review of the progression of cutaneous lupus to systemic lupus erythematosus. Front Immunol. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8963103</ArticleId><ArticleId IdType="pubmed">35359921</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xf6;nhagen C.M., Fored C.M., Granath F., Nyberg F. Increased risk of cancer among 3663 patients with cutaneous lupus erythematosus: a Swedish nationwide cohort study. Br J Dermatol. 2012;166(5):1053&#x2013;1059.</Citation><ArticleIdList><ArticleId IdType="pubmed">22175767</ArticleId></ArticleIdList></Reference><Reference><Citation>Westermann R., Zobbe K., Cordtz R., Haugaard J.H., Dreyer L. Increased cancer risk in patients with cutaneous lupus erythematosus and systemic lupus erythematosus compared with the general population: a Danish nationwide cohort study. Lupus. 2021;30(5):752&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pubmed">33497306</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu S., Lan C.C.E. Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment. Int J Mol Sci. 2017;18(10):2211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5666891</ArticleId><ArticleId IdType="pubmed">29065479</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwinnutt J.M., Wieczorek M., Balanescu A., et al. 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2022;82:48. annrheumdis-2021-222020.</Citation><ArticleIdList><ArticleId IdType="pubmed">35260387</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnett D.K., Blumenthal R.S., Albert M.A., et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;140(11):e596&#x2013;e646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7734661</ArticleId><ArticleId IdType="pubmed">30879355</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L.N., Nambudiri V.E. Cutaneous lupus erythematosus and cardiovascular disease: current knowledge and insights into pathogenesis. Clin Rheumatol. 2021;40(2):491&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">32623651</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesselvig J.H., Ahlehoff O., Dreyer L., Gislason G., Kofoed K. Cutaneous lupus erythematosus and systemic lupus erythematosus are associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. Lupus. 2017;26(1):48&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">27235406</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A.G., Crowson C.S., Singh S., et al. Risk of cerebrovascular accidents and ischemic heart disease in cutaneous lupus erythematosus: a population-based cohort study: cardiovascular disease risk in cutaneous Lupus. Arthritis Care Res. 2016;68(11):1664&#x2013;1670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5292935</ArticleId><ArticleId IdType="pubmed">27015109</ArticleId></ArticleIdList></Reference><Reference><Citation>Keyes E., Grinnell M., Jacoby D., et al. Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis. Int J Womens Dermatol. 2021;7(5):560&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8721062</ArticleId><ArticleId IdType="pubmed">35024413</ArticleId></ArticleIdList></Reference><Reference><Citation>Shams-Eldin A.N., Yafasova A., Faurschou M., et al. Long-term risk of adverse cardiovascular outcomes associated with cutaneous lupus erythematosus: a nationwide cohort study. Clin Rheumatol. 2022;41(11):3525&#x2013;3536.</Citation><ArticleIdList><ArticleId IdType="pubmed">35907102</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahlehoff O., Wu J.J., Rauns&#xf8; J., et al. Cutaneous lupus erythematosus and the risk of deep venous thrombosis and pulmonary embolism: a Danish nationwide cohort study. Lupus. 2017;26(13):1435&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pubmed">28618892</ArticleId></ArticleIdList></Reference><Reference><Citation>Boch K., Zirpel H., Thaci D., et al. Mortality in eight autoimmune bullous diseases: a global large-scale retrospective cohort study. J&#xa0;Eur Acad Dermatol Venereol. 2022;37:e535.</Citation><ArticleIdList><ArticleId IdType="pubmed">36308041</ArticleId></ArticleIdList></Reference><Reference><Citation>Kridin K., Ludwig R.J. Isotretinoin and the risk of psychiatric disturbances - a global study shedding new light on a debatable story. J&#xa0;Am Acad Dermatol. 2022;S0190-9622(22):2923&#x2013;2931.</Citation><ArticleIdList><ArticleId IdType="pubmed">36273659</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Agostino R.B., Vasan R.S., Pencina M.J., et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117(6):743&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">18212285</ArticleId></ArticleIdList></Reference><Reference><Citation>Ujiie H., Rosmarin D., Sch&#xf6;n M.P., et al. Unmet medical needs in chronic, non-communicable inflammatory skin diseases. Front Med. 2022;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9218547</ArticleId><ArticleId IdType="pubmed">35755063</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindhardsen J., Kristensen S.L., Ahlehoff O. Management of cardiovascular risk in patients with chronic inflammatory diseases: current evidence and future perspectives. Am J Cardiovasc Drugs. 2016;16(1):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26293235</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel J., T&#xfc;ting T. Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches. Exp Dermatol. 2007;16(5):454&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">17437489</ArticleId></ArticleIdList></Reference><Reference><Citation>Fetter T., Braegelmann C., de Vos L., Wenzel J. Current concepts on pathogenic mechanisms and histopathology in cutaneous lupus erythematosus. Front Med. 2022;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9196867</ArticleId><ArticleId IdType="pubmed">35712102</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6(7):508&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16778830</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanasescu C., Balanescu E., Balanescu P., et al. IL-17 in cutaneous lupus erythematosus. Eur J Intern Med. 2010;21(3):202&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">20493423</ArticleId></ArticleIdList></Reference><Reference><Citation>von Stebut E., Boehncke W.H., Ghoreschi K., et al. IL-17A in psoriasis and beyond: cardiovascular and metabolic implications. Front Immunol. 2020;10:3096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6974482</ArticleId><ArticleId IdType="pubmed">32010143</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith E., Prasad K.M.R., Butcher M., et al. Blockade of interleukin-17a results in reduced atherosclerosis in apolipoprotein E&#x2013;deficient mice. Circulation. 2010;121(15):1746&#x2013;1755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929562</ArticleId><ArticleId IdType="pubmed">20368519</ArticleId></ArticleIdList></Reference><Reference><Citation>Achuthan S., Ahluwalia J., Shafiq N., et al. Hydroxychloroquine's efficacy as an antiplatelet agent study in healthy volunteers: a proof of concept study. J&#xa0;Cardiovasc Pharmacol Ther. 2015;20(2):174&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">25125385</ArticleId></ArticleIdList></Reference><Reference><Citation>Akarsu S., Ozbagcivan O., Semiz F., Aktan S. High prevalence of metabolic syndrome in patients with discoid lupus erythematosus: a cross-sectional, case-control study. J&#xa0;Immunol Res. 2017;2017:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5239982</ArticleId><ArticleId IdType="pubmed">28127570</ArticleId></ArticleIdList></Reference><Reference><Citation>Drenkard C., Theis K.A., Daugherty T.T., et al. Depression, stigma and social isolation: the psychosocial trifecta of primary chronic cutaneous lupus erythematosus, a cross-sectional and path analysis. Lupus Sci Med. 2022;9(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9379542</ArticleId><ArticleId IdType="pubmed">35953237</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiga T. Depression and cardiovascular diseases. J&#xa0;Cardiol. 2022</Citation><ArticleIdList><ArticleId IdType="pubmed">36410589</ArticleId></ArticleIdList></Reference><Reference><Citation>Heine G., Lahl A., M&#xfc;ller C., Worm M. Vitamin D deficiency in patients with cutaneous lupus erythematosus is prevalent throughout the year: vitamin D deficiency in CLE. Br J Dermatol. 2010;163(4):863&#x2013;865.</Citation><ArticleIdList><ArticleId IdType="pubmed">20662833</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins D., Wolf M., Pan D., et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the third national health and nutrition examination survey. Arch Intern Med. 2007;167(11):1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">17563024</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M., Costenbader K., Daikh D., et al. 2019 European League against rheumatism/American College of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400&#x2013;1412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>